NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Price Target & More

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics Inc (NASDAQ:FPRX) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.08. The biotechnology company earned $32.49 million during the quarter, compared to analysts' expectations of $37.50 million. Five Prime Therapeutics had a negative return on equity of 44.36% and a negative net margin of 221.74%. View Five Prime Therapeutics' Earnings History.

7 brokers have issued 12-month target prices for Five Prime Therapeutics' shares. Their forecasts range from $17.00 to $60.00. On average, they expect Five Prime Therapeutics' share price to reach $34.7143 in the next year. View Analyst Ratings for Five Prime Therapeutics.

Some companies that are related to Five Prime Therapeutics include Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akcea Therapeutics (AKCA), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), Endo International (ENDP), Insmed (INSM), Spectrum Pharmaceuticals (SPPI), Prestige Brands (PBH), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Akorn (AKRX), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT) and Myokardia (MYOK).

News coverage about FPRX stock has trended somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Five Prime Therapeutics earned a daily sentiment score of 0.16 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.07 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Five Prime Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), Victory Capital Management Inc. (3.04%), Dimensional Fund Advisors LP (2.96%), BB Biotech AG (2.78%), Rock Springs Capital Management LP (1.66%) and Northern Trust Corp (1.05%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

FPRX stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Citigroup Inc., Spark Investment Management LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Five Prime Therapeutics.

FPRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rock Springs Capital Management LP, BB Biotech AG, DekaBank Deutsche Girozentrale, Victory Capital Management Inc., Millennium Management LLC, UBS Group AG and State of Wisconsin Investment Board. View Insider Buying and Selling for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $17.38.

Five Prime Therapeutics has a market capitalization of $603.14 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.